Hi-Tech Pharmacal Co. (HITK) Misses Q4 EPS by 8c; Revs Light

Hi-Tech Pharmacal Co. (NASDAQ: HITK) reported Q4 EPS of $0.79, $0.08 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $55.63 million versus the consensus estimate of $55.73 million.

For earnings history and earnings-related data on Hi-Tech Pharmacal Co. (HITK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c